Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.

BACKGROUND/AIM: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.

PATIENTS AND METHODS

Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.

RESULTS

Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.

CONCLUSION

PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.